Cargando…

A New Penicillin?

The spectre of antimicrobial resistance looms very large indeed in the 21st century; the supply of efficacious conventional drugs is short and not guaranteed, for various reasons. It is time to look elsewhere for answers and for protocols which might be used in tandem with our diminishing arsenal in...

Descripción completa

Detalles Bibliográficos
Autor principal: Wainwright, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175144/
https://www.ncbi.nlm.nih.gov/pubmed/32168863
http://dx.doi.org/10.3390/antibiotics9030117
_version_ 1783524769166000128
author Wainwright, Mark
author_facet Wainwright, Mark
author_sort Wainwright, Mark
collection PubMed
description The spectre of antimicrobial resistance looms very large indeed in the 21st century; the supply of efficacious conventional drugs is short and not guaranteed, for various reasons. It is time to look elsewhere for answers and for protocols which might be used in tandem with our diminishing arsenal in order to protect vital drugs. This could bridge the gap before new development in conventional antimicrobial therapy occurs, or might be a longer-term solution, particularly in the area of infectious disease prophylaxis (conventional-sensitive or -resistant). Reliable and safe protocols have been developed for the use of photoantimicrobials in this respect, offering much greater coverage, in terms of the microbial target, than Fleming ever imagined.
format Online
Article
Text
id pubmed-7175144
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71751442020-04-28 A New Penicillin? Wainwright, Mark Antibiotics (Basel) Commentary The spectre of antimicrobial resistance looms very large indeed in the 21st century; the supply of efficacious conventional drugs is short and not guaranteed, for various reasons. It is time to look elsewhere for answers and for protocols which might be used in tandem with our diminishing arsenal in order to protect vital drugs. This could bridge the gap before new development in conventional antimicrobial therapy occurs, or might be a longer-term solution, particularly in the area of infectious disease prophylaxis (conventional-sensitive or -resistant). Reliable and safe protocols have been developed for the use of photoantimicrobials in this respect, offering much greater coverage, in terms of the microbial target, than Fleming ever imagined. MDPI 2020-03-11 /pmc/articles/PMC7175144/ /pubmed/32168863 http://dx.doi.org/10.3390/antibiotics9030117 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Wainwright, Mark
A New Penicillin?
title A New Penicillin?
title_full A New Penicillin?
title_fullStr A New Penicillin?
title_full_unstemmed A New Penicillin?
title_short A New Penicillin?
title_sort new penicillin?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175144/
https://www.ncbi.nlm.nih.gov/pubmed/32168863
http://dx.doi.org/10.3390/antibiotics9030117
work_keys_str_mv AT wainwrightmark anewpenicillin
AT wainwrightmark newpenicillin